Literature DB >> 12202858

The endothelin antagonist BQ123 reduces pulmonary vascular resistance after surgical intervention for congenital heart disease.

Ingram Schulze-Neick1, Jia Li, Jayne A Reader, Lara Shekerdemian, Andrew N Redington, Daniel J Penny.   

Abstract

OBJECTIVE: Postoperative pulmonary hypertension in children after surgical intervention for congenital heart disease has been attributed to failure of the pulmonary endothelium to provide adequate vasodilation. Although we have shown that the impaired vasodilatory component attributable to the l-arginine-nitric oxide pathway is almost completely reversible, a nonrestorable component persists, implying an additional vasoconstrictive mechanism in postoperative pulmonary endothelial dysfunction. In this study of children after surgical intervention for congenital heart disease, we measured endothelin-1 levels and used BQ123, a selective endothelin-A receptor antagonist, together with inhaled nitric oxide to discriminate dysfunctional pulmonary endothelial vasodilation from endothelin-mediated pulmonary vasoconstriction.
METHODS: All children were examined early after surgical intervention in the intensive care unit. Pulmonary vascular resistance (with respiratory mass spectrometry), as well as arterial and venous endothelin-1 levels (measured by means of a quantitative enzyme-linked immunosorbent assay), were determined in 7 children (age range, 3.3-13.7 months; median age, 6.3 months) with intracardiac shunting defects at baseline and during ventilation with a fraction of inspired oxygen of 0.65, with additional BQ123 (0.1 mg/kg infused over 20 minutes), and with inhaled nitric oxide (20 ppm).
RESULTS: Pulmonary vascular resistance decreased from 7.7 +/- 3.4 at baseline to 6.1 +/- 2.8 Woods units. m(-2) (P =.022) at a fraction of inspired oxygen of 0.65 and to 4.7 +/- 2.7 Woods units. m(-2) (P =.013) during BQ123 infusion. Inhaled nitric oxide had no further effect on pulmonary vascular resistance. Left atrial endothelin-1 levels (1.35-5.12 pg/mL; mean, 2.4 pg/mL) correlated significantly with the decrease in pulmonary vascular resistance in response to BQ123 infusion (r(2) = 0.89, P =.003).
CONCLUSION: Postoperative elevation of pulmonary vascular resistance in children after surgical intervention for congenital heart disease is responsive to endothelin-A blockade with BQ123. Increased levels of endothelin-1 predict the response to this therapy, which might become an important addition to the clinical armamentarium in postoperative pulmonary hypertensive disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12202858     DOI: 10.1067/mtc.2002.121492

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  8 in total

Review 1.  Severe paediatric pulmonary hypertension: new management strategies.

Authors:  A Rashid; D Ivy
Journal:  Arch Dis Child       Date:  2005-01       Impact factor: 3.791

2.  Endothelin-A receptor blockade prevents and partially reverses neonatal hypoxic pulmonary vascular remodeling.

Authors:  Namasivayam Ambalavanan; Arlene Bulger; Joanne Murphy-Ullrich; Suzanne Oparil; Yiu-Fai Chen
Journal:  Pediatr Res       Date:  2005-03-17       Impact factor: 3.756

3.  EDNRA variants associate with smooth muscle mRNA levels, cell proliferation rates, and cystic fibrosis pulmonary disease severity.

Authors:  Rebecca Darrah; Edward McKone; Clare O'Connor; Christine Rodgers; Alan Genatossio; Sharon McNamara; Ronald Gibson; J Stuart Elborn; Madeleine Ennis; Charles G Gallagher; Noor Kalsheker; Moira Aitken; Dawn Wiese; John Dunn; Paul Smith; Rhonda Pace; Douglas Londono; Katrina A B Goddard; Michael R Knowles; Mitchell L Drumm
Journal:  Physiol Genomics       Date:  2009-12-22       Impact factor: 3.107

Review 4.  Systemic oxygen transport derived by using continuous measured oxygen consumption after the Norwood procedure-an interim review.

Authors:  Jia Li
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-03-28

Review 5.  Pharmacotherapy for pulmonary hypertension.

Authors:  Robin H Steinhorn
Journal:  Pediatr Clin North Am       Date:  2012-08-26       Impact factor: 3.278

Review 6.  Pulmonary Hypertension.

Authors:  Peter Oishi; Jeffrey R Fineman
Journal:  Pediatr Crit Care Med       Date:  2016-08       Impact factor: 3.624

7.  Intravenous sildenafil and inhaled nitric oxide: a randomised trial in infants after cardiac surgery.

Authors:  Christian Stocker; Daniel J Penny; Christian P Brizard; Andrew D Cochrane; Rodrigo Soto; Lara S Shekerdemian
Journal:  Intensive Care Med       Date:  2003-10-07       Impact factor: 17.440

8.  Treatment With Endothelin-A Receptor Antagonist BQ123 Attenuates Acute Inflammation in Mice Through T-Cell-Dependent Polymorphonuclear Myeloid-Derived Suppressor Cell Activation.

Authors:  Ziyang Chen; Xiaogang Zhang; Shuaijun Lv; Zhe Xing; Mengyu Shi; Xinyao Li; Meiqi Chen; Shaowen Zuo; Yingxu Tao; Gang Xiao; Jingping Liu; Yumei He
Journal:  Front Immunol       Date:  2021-03-22       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.